TY - JOUR
T1 - AACR project genie
T2 - Powering precision medicine through an international consortium
AU - The AACR Project GENIE Consortium
AU - Sweeney, S. M.
AU - Cerami, E.
AU - Baras, A.
AU - Pugh, T. J.
AU - Schultz, N.
AU - Stricker, T.
AU - Lindsay, J.
AU - Del Vecchio Fitz, C.
AU - Kumari, P.
AU - Micheel, C.
AU - Shaw, K.
AU - Gao, J.
AU - Moore, N.
AU - Stricker, T.
AU - Kandoth, C.
AU - Reardon, B.
AU - Lepisto, E.
AU - Gardos, S.
AU - Dang, K.
AU - Guinney, J.
AU - Omberg, L.
AU - Yu, T.
AU - Gross, B.
AU - Heins, Z.
AU - Hyman, D.
AU - Rollins, B.
AU - Sawyers, C.
AU - Solit, D.
AU - Schrag, D.
AU - Velculescu, V.
AU - Andre, F.
AU - Bedard, P.
AU - Levy, M.
AU - Meijer, G.
AU - Rollins, B.
AU - Shaw, K.
N1 - Funding Information:
This study was supported by Howard Hughes Medical Institute (C.L. Sawyers); NCI grant CA008748 (Memorial Sloan Kettering Cancer Center); Princess Margaret Cancer Foundation, Cancer Core Ontario Applied Clinical Research Unit, University of Toronto Division of Medical Oncology Strategic Innovation, Ontario Ministry of Health & Long Term Care Academic Health Services Centre, and Funding Plan Innovation Award (University Health Network, Princess Margaret); Susan G. Komen SAC110052 and NIH Grants 5U01CA168394, 5P50CA098258, 5P50CA083639, U54HG008100, U24CA210950, and U24CA209851, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and CCSG Grant CA016672 (G.B. Mills); NCI grant CA016672 and CPRIT RP150535 Precision Oncology Decision Support Core Grant (University of Texas MD Anderson Cancer Center); NCI core grant 2P30CA006516-52 (Dana-Farber Cancer Center); T.J. Martell Foundation and CCSG 5P30CA068485-21 (Vanderbilt-Ingram Cancer Center); NCI core grant CA006973 (Sidney Kimmel Cancer Center at Johns Hopkins University), Maryland Cigarette Restitution Fund Research Grant (A. Baras), and CA121113, CA180950, Commonwealth Foundation, and Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (V.E. Velculescu); Pfizer and Eli Lilly (M. Arnedos); and Dutch Ministry of Health (Dutch National Cancer Institute), Dutch Cancer Society, Pilot Infrastructure Initiative Project #8166 and Translational Research IT (TraIT) in transition to Health-RI, sustaining support for translational cancer research (M. Bierkens and J. van Denderen).
Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2017
Y1 - 2017
N2 - The AACR Project GENIE is an international data-sharing consortium focused on generating an evidence base for precision cancer medicine by integrating clinical-grade cancer genomic data with clinical outcome data for tens of thousands of cancer patients treated at multiple institutions worldwide. In conjunction with the first public data release from approximately 19,000 samples, we describe the goals, structure, and data standards of the consortium and report conclusions from high-level analysis of the initial phase of genomic data. We also provide examples of the clinical utility of GENIE data, such as an estimate of clinical actionability across multiple cancer types (>30%) and prediction of accrual rates to the NCI-MATCH trial that accurately reflect recently reported actual match rates. The GENIE database is expected to grow to >100,000 samples within 5 years and should serve as a powerful tool for precision cancer medicine. SIGNIFICANCE: The AACR Project GENIE aims to catalyze sharing of integrated genomic and clinical datasets across multiple institutions worldwide, and thereby enable precision cancer medicine research, including the identification of novel therapeutic targets, design of biomarker-driven clinical trials, and identification of genomic determinants of response to therapy.
AB - The AACR Project GENIE is an international data-sharing consortium focused on generating an evidence base for precision cancer medicine by integrating clinical-grade cancer genomic data with clinical outcome data for tens of thousands of cancer patients treated at multiple institutions worldwide. In conjunction with the first public data release from approximately 19,000 samples, we describe the goals, structure, and data standards of the consortium and report conclusions from high-level analysis of the initial phase of genomic data. We also provide examples of the clinical utility of GENIE data, such as an estimate of clinical actionability across multiple cancer types (>30%) and prediction of accrual rates to the NCI-MATCH trial that accurately reflect recently reported actual match rates. The GENIE database is expected to grow to >100,000 samples within 5 years and should serve as a powerful tool for precision cancer medicine. SIGNIFICANCE: The AACR Project GENIE aims to catalyze sharing of integrated genomic and clinical datasets across multiple institutions worldwide, and thereby enable precision cancer medicine research, including the identification of novel therapeutic targets, design of biomarker-driven clinical trials, and identification of genomic determinants of response to therapy.
UR - http://www.scopus.com/inward/record.url?scp=85026862883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026862883&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-17-0151
DO - 10.1158/2159-8290.CD-17-0151
M3 - Article
C2 - 28572459
AN - SCOPUS:85026862883
SN - 2159-8274
VL - 7
SP - 818
EP - 831
JO - Cancer discovery
JF - Cancer discovery
IS - 8
ER -